Referências
Principais artigos
Joly P, Horvath B, Patsatsi Α, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol. 2020 Sep;34(9):1900-13.Texto completo Resumo
Antiga E, Bech R, Maglie R, et al. S2k guidelines on the management of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2023 Jun;37(6):1118-34.Texto completo Resumo
Murrell DF, Peña S, Joly P, et al. Diagnosis and management of pemphigus: recommendations of an international panel of experts. J Am Acad Dermatol. 2020 Mar;82(3):575-85.e1.Texto completo Resumo
Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017 May 20;389(10083):2031-40. Resumo
Artigos de referência
1. Joly P, Horvath B, Patsatsi Α, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol. 2020 Sep;34(9):1900-13.Texto completo Resumo
2. Hsu YM, Fang HY, Lin CL, et al. The risk of depression in patients with pemphigus: a nationwide cohort study in Taiwan. Int J Environ Res Public Health. 2020 Mar 17;17(6):1983.Texto completo Resumo
3. Sajda T, Sinha AA. Autoantibody signaling in pemphigus vulgaris: development of an integrated model. Front Immunol. 2018;9:692.Texto completo Resumo
4. Mutasim DF, Pelc NJ, Anhalt GJ. Paraneoplastic pemphigus. Dermatol Clin. 1993 Jul;11(3):473-81. Resumo
5. Kasperkiewicz M, Ellebrecht CT, Takahashi H, et al. Pemphigus. Nat Rev Dis Primers. 2017 May 11;3:17026. Resumo
6. Simon DG, Krutchkoff D, Kaslow RA, et al. Pemphigus in Hartford County, Connecticut, from 1972 to 1977. Arch Dermatol. 1980 Sep;116(9):1035-7. Resumo
7. Porro AM, Seque CA, Ferreira MCC, et al. Pemphigus vulgaris. An Bras Dermatol. 2019 Jul 29;94(3):264-78.Texto completo Resumo
8. Rosi-Schumacher M, Baker J, Waris J, et al. Worldwide epidemiologic factors in pemphigus vulgaris and bullous pemphigoid. Front Immunol. 2023 Apr;14:1159351.Texto completo Resumo
9. Wertenteil S, Garg A, Strunk A, et al. Prevalence Estimates for Pemphigus in the United States: A Sex- and Age-Adjusted Population Analysis. JAMA Dermatol. 2019 May 1;155(5):627-9.Texto completo Resumo
10. Kridin K, Schmidt E. Epidemiology of pemphigus. JID Innov. 2021 Mar;1(1):100004.Texto completo Resumo
11. Zhao L, Chen Y, Wang M. The global incidence rate of pemphigus vulgaris: a systematic review and meta-analysis. Dermatology. 2023;239(4):514-22. Resumo
12. Jelti L, Cordel N, Gillibert A, et al. Incidence and mortality of pemphigus in France. J Invest Dermatol. 2019 Feb;139(2):469-73.Texto completo Resumo
13. Lee YB, Lee JH, Lee SY, et al. Incidence and death rate of pemphigus vulgaris and pemphigus foliaceus in Korea: a nationwide, population-based study (2006-2015). J Dermatol. 2018 Dec;45(12):1396-1402. Resumo
14. Försti AK, Vuorre O, Laurila E, et al. Pemphigus foliaceus and pemphigus erythematosus are the most common subtypes of pemphigus in Northern Finland. Acta Derm Venereol. 2019 Nov 1;99(12):1127-30. Resumo
15. Hans-Filho G, dos Santos V, Katayama JH, et al. An active focus of high prevalence of fogo selvagem on an Amerindian reservation in Brazil. Cooperative Group on Fogo Selvagem Research. J Invest Dermatol. 1996 Jul;107(1):68-75. Resumo
16. Antiga E, Bech R, Maglie R, et al. S2k guidelines on the management of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2023 Jun;37(6):1118-34.Texto completo Resumo
17. Quintarelli L, Coi A, Maglie R, et al. Clinical patterns, survival, comorbidities, and treatment regimens in 149 patients with pemphigus in tuscany (Italy): a 12-year hospital-based study. Front Immunol. 2022 Jul;13:895490.Texto completo Resumo
18. Anhalt GJ, Kim SC, Stanley JR, et al. Paraneoplastic pemphigus - an autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med. 1990 Dec 20;323(25):1729-35.Texto completo Resumo
19. Anderson HJ, Huang S, Lee JB. Paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome: part I. clinical overview and pathophysiology. J Am Acad Dermatol. 2024 Jul;91(1):1-10. Resumo
20. Diaz LA, Sampaio SA, Rivitti EA, et al. Endemic pemphigus foliaceus (fogo selvagem): II. Current and historical epidemiological aspects. J Invest Dermatol. 1989;92:4-12. Resumo
21. Vernal S, Pepinelli M, Casanova C, et al. Insights into the epidemiological link between biting flies and pemphigus foliaceus in southeastern Brazil. Acta Trop. 2017 Dec;176:455-62. Resumo
22. Aoki V, Millikan RC, Diaz LA, et al. Environmental risk factors in pemphigus foliaceus (fogo selvagem). J Investig Dermatol Symp Proc. 2004;9:34-40. Resumo
23. Qian Y, Jeong JS, Maldonado M, et al. Brazilian pemphigus foliaceus anti-desmoglein 1 autoantibodies cross-react with sand fly salivary LJM11 antigen. J Immunol. 2012 Aug 15;189(4):1535-9.Texto completo Resumo
24. Peng B, Temple BR, Yang J, et al. Identification of a primary antigenic target of epitope spreading in endemic pemphigus foliaceus. J Autoimmun. 2021 Jan;116:102561. Resumo
25. Harman KE, Gratian MJ, Bhogal BS, et al. A study of desmoglein 1 autoantibodies in pemphigus vulgaris: racial differences in frequency and the association with a more severe phenotype. Br J Dermatol. 2000 Aug;143(2):343-8. Resumo
26. Didona D, Di Zenzo G. Humoral epitope spreading in autoimmune bullous diseases. Front Immunol. 2018 Apr;9:779.Texto completo Resumo
27. Billet SE, Grando SA, Pittelkow MR. Paraneoplastic autoimmune multiorgan syndrome: review of the literature and support for a cytotoxic role in pathogenesis. Autoimmunity. 2006 Nov;39(7):617-30. Resumo
28. Alpsoy E, Akman-Karakas A, Uzun S. Geographic variations in epidemiology of two autoimmune bullous diseases: pemphigus and bullous pemphigoid. Arch Dermatol Res. 2015 May;307(4):291-8.Texto completo Resumo
29. Bordenave K, Griffith J, Hordes SM, et al. The historical and geomedical immunogenetics of pemphigus among the descendants of Sephardic Jews in New Mexico. Arch Dermatol. 2001 Jun;137(6):825-6. Resumo
30. Brenner S, Goldberg I. Drug-induced pemphigus. Clin Dermatol. Jul-Aug 2011;29(4):455-7. Resumo
31. Murrell DF, Peña S, Joly P, et al. Diagnosis and management of pemphigus: recommendations of an international panel of experts. J Am Acad Dermatol. 2020 Mar;82(3):575-85.e1.Texto completo Resumo
32. Raneses E, McGinley Simpson M, Rosenberg A, et al. A retrospective review of autoimmune bullous disease antibody positivity before clinical symptoms. J Am Acad Dermatol. 2021 Feb 4;S0190-9622(21)00315-7. Resumo
33. Leger S, Picard D, Ingen-Housz-Oro S, et al. Prognostic factors of paraneoplastic pemphigus. Arch Dermatol. 2012 Oct;148(10):1165-72.Texto completo Resumo
34. Ouedraogo E, Gottlieb J, de Masson A, et al. Risk factors for death and survival in paraneoplastic pemphigus associated with hematologic malignancies in adults. J Am Acad Dermatol. 2019 Jun;80(6):1544-9. Resumo
35. Cummins DL, Mimouni D, Tzu J, et al. Lichenoid paraneoplastic pemphigus in the absence of detectable antibodies. J Am Acad Dermatol. 2007 Jan;56(1):153-9. Resumo
36. Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017 May 20;389(10083):2031-40. Resumo
37. Tavakolpour S, Mahmoudi H, Balighi K, et al. Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review. Int Immunopharmacol. 2018 Jan;54:131-8. Resumo
38. Tedbirt B, Maho-Vaillant M, Houivet E, et al. Sustained remission without corticosteroids among patients with pemphigus who had rituximab as first-line therapy: follow-up of the ritux 3 trial. JAMA Dermatol. 2024 Mar 1;160(3):290-6.Texto completo Resumo
39. Werth VP, Joly P, Mimouni D, et al. Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris. N Engl J Med. 2021 Jun 17;384(24):2295-305.Texto completo Resumo
40. Kridin K, Mruwat N, Ludwig RJ. Association of rituximab with risk of long-term cardiovascular and metabolic outcomes in patients with pemphigus. JAMA Dermatol. 2023 Jan 1;159(1):56-61.Texto completo Resumo
41. Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. Lancet. 2019 Sep 7;394(10201):882-94. Resumo
42. Beissert S, Mimouni D, Kanwar AJ, et al. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. J Invest Dermatol. 2014 Dec;150(12):1331-5. Resumo
43. Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol. 2006 Nov;142(11):1447-54. Resumo
44. Kawashita MY, Tsai K, Aoiki V, et al. Mycophenolate mofetil as an adjuvant therapy for classic and endemic pemphigus foliaceus. J Dermatol. 2005 Jul;32(7):574-80. Resumo
45. Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007 Aug 9;357(6):545-52.Texto completo Resumo
46. Ahmed AR, Spigelman Z, Cavacini LA, et al. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006 Oct 26;355(17):1772-9.Texto completo Resumo
47. Gurcan HM, Jeph S, Ahmed AR, et al. Intravenous immunoglobulin therapy in autoimmune mucocutaneous blistering diseases: a review of the evidence for its efficacy and safety. Am J Clin Dermatol. 2010;11(5):315-26. Resumo
48. Behzad M, Möbs C, Kneisel A, et al. Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris. Br J Dermatol. 2012 Apr;166(4):844-52. Resumo
49. Frew JW, Murrell DF. Current management strategies in paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome). Dermatol Clin. 2011 Oct;29(4):607-12. Resumo
50. Czernik A, Camilleri M, Pittelkow MR, et al. Paraneoplastic autoimmune multiorgan syndrome: 20 years after. Int J Dermatol. 2011 Aug;50(8):905-14. Resumo
51. Kardos M, Levine D, Gürcan HM, et al. Pemphigus vulgaris in pregnancy: analysis of current data on the management and outcomes. Obstet Gynecol Surv. 2009 Nov;64(11):739-49. Resumo
52. Werth VP. Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids. Arch Dermatol. 1996 Dec;132(12):1435-9. Resumo
53. Mao J, Bao S, Chen Y, et al. Evaluation of combination therapy with ofatumumab and systemic corticosteroids for pemphigus: a multi-centre cohort study. J Eur Acad Dermatol Venereol. 2025 Mar;39(3):e244-7. Resumo
54. US Nation Library of Medicine. Open-label Study to Determine the Maximum Tolerated Dose of DSG3-CAART in Mucosal-dominant PV Patients (mPV). Jan 2021 [internet publication].Texto completo
55. Ren Z, Narla S, Hsu DY, et al. Association of serious infections with pemphigus and pemphigoid: analysis of the Nationwide Inpatient Sample. J Eur Acad Dermatol Venereol. 2018 Oct;32(10):1768-76. Resumo
O uso deste conteúdo está sujeito ao nosso aviso legal